ASCO: Enhertu’s Empire Expands
“Transformative” data could move Daiichi Sankyo and AstraZeneca’s conjugate into ultralow HER2 expressers, and allow its use ahead of chemo in breast cancer.
“Transformative” data could move Daiichi Sankyo and AstraZeneca’s conjugate into ultralow HER2 expressers, and allow its use ahead of chemo in breast cancer.